Lexaria Bioscience Corp. (NASDAQ:LEXX) Insider Vanessa Carle Sells 2,567 Shares of Stock

Lexaria Bioscience Corp. (NASDAQ:LEXX) insider Vanessa Carle sold 2,567 shares of Lexaria Bioscience stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $4.00, for a total transaction of $10,268.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Lexaria Bioscience Stock Performance

NASDAQ LEXX opened at $3.98 on Friday. The company has a fifty day moving average of $3.11 and a 200 day moving average of $2.90. Lexaria Bioscience Corp. has a 1 year low of $0.80 and a 1 year high of $6.85.

Institutional Trading of Lexaria Bioscience

An institutional investor recently bought a new position in Lexaria Bioscience stock. Cowen AND Company LLC purchased a new position in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 256,327 shares of the company’s stock, valued at approximately $320,000. Cowen AND Company LLC owned approximately 2.46% of Lexaria Bioscience at the end of the most recent quarter. 13.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Lexaria Bioscience in a report on Thursday, July 18th.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.